Hsiri Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Hsiri Therapeutics is a private, preclinical-stage biotech tackling the critical global health threat of antimicrobial resistance (AMR). The company is developing a pipeline of novel small molecules targeting drug-resistant mycobacterial, bacterial, and fungal infections, leveraging research from key academic collaborators. Hsiri has established a significant strategic partnership with Shionogi & Co., Ltd. for its mycobacterial programs and has received grant support from U.S. government agencies, positioning it to address substantial unmet medical needs in infectious diseases.

Infectious DiseasesMycobacterial InfectionsAntimicrobial Resistance

Technology Platform

Combination of rational drug design and serendipitous discovery for novel antimicrobial small molecules, with a focus on drug-resistant bacteria and fungi. Supported by grant funding from U.S. government agencies.

Opportunities

The global antimicrobial resistance crisis creates a large and growing unmet medical need, supported by evolving regulatory incentives (e.g., QIDP, LPAD) and potential new reimbursement models.

The strategic partnership with Shionogi provides validation, non-dilutive funding, and development expertise for the lead program.

Grant funding from U.S.

government agencies de-risks early research and extends the company's financial runway.

Risk Factors

High scientific risk associated with transitioning from preclinical discovery to clinical efficacy in complex infectious diseases.

The antimicrobial market, while needed, presents commercial challenges including pricing pressure, stewardship limiting use, and potential for slow uptake.

The company is pre-revenue and will require substantial additional capital to advance its pipeline through costly clinical trials.

Competitive Landscape

Hsiri operates in the competitive but critically underserved antimicrobial resistance space, competing with larger pharma (e.g., Merck, Pfizer) and biotechs (e.g., Entasis, Spero) developing novel agents. Differentiation will depend on the novelty, efficacy, and safety profile of its compounds. Its focused approach on mycobacterial diseases and academic collaborations may provide a niche advantage.

More companies in Small Molecule Drugs →More companies in United States →